Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 5/20 | 0.50 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12233567 | 0.83 | PDK1 (0.51) | PDK1GLRA1VNN1MAPTUSP30 | |
| SCHEMBL17776427 | 0.76 | PDK1 (0.56) | PDK1GLRA1POLBVNN1MAPT | |
| SCHEMBL15431233 | 0.76 | PDK1 (0.56) | PDK1GLRA1POLBVNN1MAPT | |
| SCHEMBL22167712 | 0.76 | PDK1 (0.56) | PDK1GLRA1POLBVNN1MAPT | |
| SCHEMBL14557428 | 0.75 | POLB (0.61) | POLBMAPTLMNAHTR1A | |
| SCHEMBL26817700 | 0.75 | PDK1 (0.51) | PDK1GLRA1POLBVNN1MAPT | |
| SCHEMBL26817711 | 0.75 | PDK1 (0.51) | PDK1GLRA1POLBVNN1MAPT | |
| SCHEMBL22681134 | 0.74 | PDK1 (0.50) | PDK1GLRA1DPP4PIK3CDRAB9A | |
| SCHEMBL9469262 | 0.74 | PDK1 (0.43) | PDK1GLRA1POLBVNN1LMNA | |
| SCHEMBL25724359 | 0.74 | PDK1 (0.46) | PDK1GLRA1POLBVNN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | PDK1 228/4885GLRA1 2883/4885POLB 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.